What is Exagen?
Headquartered in the United States, Exagen specializes in the development and commercialization of proprietary diagnostic testing solutions, most notably under its AVISE brand. The company utilizes innovative biomarkers to provide clarity in clinical decision-making, specifically targeting conditions such as lupus and rheumatoid arthritis. By bridging the gap between scientific discovery and patient-centered care, Exagen has established a robust market position, transforming how clinicians detect and monitor chronic autoimmune diseases through research-driven diagnostic innovation.
How much funding has Exagen raised?
Exagen has raised a total of $258.3M across 15 funding rounds:
Series D
$5M
Debt
$25M
Debt
$4M
Debt
$1.8M
Debt
$3M
Series E
$16.8M
Debt
$2.1M
Series F
$23M
Debt
$25M
Private Equity
$22.6M
Stock Offering
$58M
Stock/Share Issuance
$20.2M
Series D (2013): $5M featuring CRG L.P.
Debt (2013): $25M backed by Capital Royalty Partners
Debt (2014): $4M with participation from Sun Mountain Capital
Debt (2015): $1.8M, investors not publicly disclosed
Debt (2015): $3M, investors not publicly disclosed
Series E (2016): $16.8M, investors not publicly disclosed
Debt (2016): $2.1M, investors not publicly disclosed
Series F (2017): $23M, investors not publicly disclosed
Debt (2017): $25M led by Innovatus Capital Partners, LLC
Private Equity (2019): $22.6M supported by H.I.G. BioHealth Partners, Hunt Holdings, Tullis Health Funds, and Sun Mountain
Stock Issuance/Offering (2019): $58M featuring Undisclosed
Stock/Share Issuance (2025): $20.2M, investors not publicly disclosed
Key Investors in Exagen
Tullis Health Investors
A private equity firm specializing in high-growth, commercial-stage healthcare companies, focusing on medical devices, biotechnology, and specialty pharmaceuticals to drive global health outcomes.
Sun Mountain Capital
A Santa Fe-based private equity firm with diverse investment strategies spanning venture capital, private credit, and growth equity across the life sciences and technology sectors.
Mesa Verde Venture Partners
An early-stage life sciences venture capital firm dedicated to partnering with biomedical entrepreneurs to build successful companies in diagnostics, medical devices, and digital health.
What's next for Exagen?
With the recent influx of capital, Exagen is well-positioned to accelerate its research and development initiatives, further expanding its portfolio of diagnostic technologies. The company's strategic focus remains on enhancing the accuracy and timing of disease detection, which is essential for improving patient outcomes in the competitive life sciences landscape. As Exagen moves into its next phase of growth, the firm is expected to leverage its deep-tech expertise to scale its commercial operations and solidify its influence in the global healthcare diagnostics market.
See full Exagen company page
